恒瑞医药(01276)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

01276 恒瑞医药

未开盘 05-26 16:08:22

59.650

-1.700

-2.77%

最高61.800	最低59.500	成交量367.04万
今开61.000	昨收61.350	日振幅3.75%
总市值3,959亿	流通市值153.90亿	总股本66.37亿
成交额2.21亿	换手率1.42%	流通股本2.58亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"01276","market":"HK","secType":"STK","nameCN":"恒瑞医药","latestPrice":59.65,"timestamp":1779782902003,"preClose":61.35,"halted":0,"volume":3670435,"delay":0,"changeRate":-0.02770986145069279,"floatShares":258000000,"shares":6637000000,"eps":1.3626900502307795,"marketStatus":"未开盘","change":-1.7,"latestTime":"05-26 16:08:22","open":61,"high":61.8,"low":59.5,"amount":221359479,"amplitude":0.03749,"askPrice":59.7,"askSize":31000,"bidPrice":59.65,"bidSize":13200,"shortable":3,"etf":0,"ttmEps":1.409712095540353,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1779845400000},"marketStatusCode":0,"adr":0,"listingDate":1747929600000,"exchange":"SEHK","adjPreClose":61.35,"dividendRate":0.003869,"openAndCloseTimeList":[[1779759000000,1779768000000],[1779771600000,1779782400000]],"volumeRatio":1.105623510730337,"lotSize":200,"spreadScale":0,"tradeCurrency":"HKD","astockBrief":{"symbol":"600276","market":"SH","secType":"STK","nameCN":"恒瑞医药","latestPrice":49.2,"timestamp":1779778800000,"preClose":49.43,"halted":0,"volume":71374500,"delay":0,"premium":"+4.99"}},"requestUrl":"/m/hq/s/01276","defaultTab":"news","newsList":[{"id":"2638592066","title":"恒瑞医药(600276.SH)：HRS-1635片获得药物临床试验批准通知书","url":"https://stock-news.laohu8.com/highlight/detail?id=2638592066","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2638592066?lang=zh_cn&edition=full","pubTime":"2026-05-26 16:49","pubTimestamp":1779785384,"startTime":"0","endTime":"0","summary":"智通财经APP讯，恒瑞医药(600276.SH)发布公告，近日，公司子公司成都盛迪医药有限公司收到国家药品监督管理局核准签发关于HRS-1635片的《药物临床试验批准通知书》，将于近期开展临床试验。HRS-1635片是公司自主研发的创新型抗肿瘤药物，拟用于治疗B细胞恶性肿瘤。经查询，目前国内外暂无同类药物获批上市。截至目前，HRS-1635片相关项目累计研发投入约2,360万元(未经审计)。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1445986.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0012","LU1146622755.USD","LU1580142542.USD","LU2495084118.USD","LU2097828631.EUR","BK1191","LU2580892862.HKD","BK0196","BK0060","LU1820825898.SGD","LU2097828557.USD","LU0405327148.USD","LU2148510915.USD","LU1064130708.USD","LU1655091616.SGD","LU1997245094.SGD","01276","LU1969619763.USD","BK0188","LU0405327494.USD","LU1023057109.AUD","LU2289578879.USD","LU1064131003.USD","BK0239","LU1997245177.USD","LU2097828714.EUR","LU2580892789.USD","BK0183","LU2097828474.EUR","LU2328871848.SGD","BK0028","LU1255011170.USD","LU0359201885.HKD","LU2543165471.USD","LU1328615791.USD","LU0359202008.SGD","LU2488822045.USD","LU2097828805.USD","600276","LU1997244956.HKD","LU1781817850.SGD","LU0359201612.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638558983","title":"恒瑞医药：公司2025年度利润分配方案经公司2025年年度股东会审议通过","url":"https://stock-news.laohu8.com/highlight/detail?id=2638558983","media":"证券日报","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2638558983?lang=zh_cn&edition=full","pubTime":"2026-05-25 20:21","pubTimestamp":1779711660,"startTime":"0","endTime":"0","summary":"证券日报网讯5月25日，恒瑞医药在互动平台回答投资者提问时表示，公司2025年度利润分配方案经公司2025年年度股东会审议通过，将按既定方案进行，具体详见公司在交易所网站发布的公告。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202605253748385364.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU1328615791.USD","LU1820825898.SGD","01276","LU0405327148.USD","LU2289578879.USD","LU2580892862.HKD","BK0028","LU1580142542.USD","BK1191","LU2097828805.USD","BK0060","LU2097828474.EUR","BK0012","LU2097828631.EUR","LU1969619763.USD","LU2097828557.USD","BK0183","LU1023057109.AUD","LU1655091616.SGD","LU0359201612.USD","LU2097828714.EUR","LU2580892789.USD","LU2488822045.USD","LU2148510915.USD","LU1146622755.USD","600276","LU1064130708.USD","LU1255011170.USD","LU1997245094.SGD","LU2495084118.USD","BK0188","LU0359201885.HKD","LU1997245177.USD","LU0359202008.SGD","LU2328871848.SGD","LU1781817850.SGD","LU1997244956.HKD","LU0405327494.USD","LU2543165471.USD","BK0239","BK0196","LU1064131003.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638535260","title":"智通AH统计|5月25日","url":"https://stock-news.laohu8.com/highlight/detail?id=2638535260","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2638535260?lang=zh_cn&edition=full","pubTime":"2026-05-25 16:15","pubTimestamp":1779696907,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，截止5月25日收盘，东北电气、浙江世宝、安德利果汁分列AH溢价率前三位，溢价率分别为610.53%、402.67%、321.80%；宁德时代、兆易创新、招商银行分列AH溢价率末三位，溢价率分别为-29.65%、-20.62%、-4.35%。其中大唐发电、安德利果汁、浙江世宝的偏离值位居前三，分别为82.87%、66.90%、53.24%；另外，上海电气、龙旗科技、京城机电股份的偏离值位居后三，分别为-33.54%、-17.88%、-17.86%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1445579.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["03986","02899","02727","00553","03296","PAImain","02601","03678","01349","06127","06613","82318","01276","00719","02318","02359","80883","LU1115378108.SGD","00916","PNGAY","01812","00187","00300","00981","00883","159982","01171","01800","EWH","02628","03968","02218","03750","06031","00895","399300","01108","09611","HPAD.SI","601318","00042","03145","03143","01033","00991","LU0651947912.USD","01057","02338","00956"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637126963","title":"恒瑞医药：2025年公司创新药销售收入163.42亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2637126963","media":"证券日报","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2637126963?lang=zh_cn&edition=full","pubTime":"2026-05-22 20:59","pubTimestamp":1779454740,"startTime":"0","endTime":"0","summary":"证券日报网讯5月22日，恒瑞医药在互动平台回答投资者提问时表示，公司坚持科技创新战略，已在中国获批上市24款1类创新药、5款2类新药，另有100多个自主创新产品正在临床开发，400余项临床试验在国内外开展。经营业绩方面，创新成果转化高效赋能，创新药销售引领业绩增长。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202605223747010910.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU1328615791.USD","LU1820825898.SGD","01276","LU0405327148.USD","LU2289578879.USD","LU2580892862.HKD","BK0028","BK1574","LU1580142542.USD","BK1191","LU2097828805.USD","BK0060","LU2097828474.EUR","BK0012","LU2097828631.EUR","LU1969619763.USD","LU2097828557.USD","BK0183","BK1161","LU1023057109.AUD","LU1655091616.SGD","LU0359201612.USD","LU2097828714.EUR","LU2580892789.USD","LU2488822045.USD","LU2148510915.USD","LU1146622755.USD","600276","LU1064130708.USD","LU1255011170.USD","LU1997245094.SGD","LU2495084118.USD","BK0188","LU0359201885.HKD","LU1997245177.USD","LU0359202008.SGD","LU2328871848.SGD","LU1781817850.SGD","LU1997244956.HKD","LU0405327494.USD","159992","LU2543165471.USD","BK0239","BK0196","06978","LU1064131003.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637391065","title":"智通AH统计|5月22日","url":"https://stock-news.laohu8.com/highlight/detail?id=2637391065","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2637391065?lang=zh_cn&edition=full","pubTime":"2026-05-22 16:15","pubTimestamp":1779437706,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，截止5月22日收盘，东北电气、浙江世宝、弘业期货分列AH溢价率前三位，溢价率分别为610.53%、386.64%、304.56%；宁德时代、兆易创新、招商银行分列AH溢价率末三位，溢价率分别为-28.21%、-27.83%、-4.15%。其中大唐发电、东北电气、浙江世宝的偏离值位居前三，分别为86.78%、45.81%、39.50%；另外，上海电气、龙旗科技、东江环保的偏离值位居后三，分别为-34.55%、-20.97%、-16.41%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1445017.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["03750","03678","82318","00300","02338","03986","601318","03143","01800","00956","02691","IE0008369823.USD","02359","02628","00981","00553","01276","03296","02899","HPAD.SI","06613","01033","00501","06127","00895","06031","00883","02318","399300","01171","00187","EWH","01057","02727","01108","03968","01812","03145","PNGAY","01349","02218","00042","02476","PAImain","00991","09611","159982","80883","00916"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1191905171","title":"异动解读｜恒瑞医药盘中上涨3.44%，BMS合作后连续回调企稳反弹","url":"https://stock-news.laohu8.com/highlight/detail?id=1191905171","media":"行情直击","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1191905171?lang=zh_cn&edition=full","pubTime":"2026-05-21 13:09","pubTimestamp":1779340193,"startTime":"0","endTime":"0","summary":"5月21日，恒瑞医药盘中上涨3.44%，报63.15港元，成交额1.06亿港元。此前公司与百时美施贵宝达成潜在总额约152亿美元的全球战略合作协议，消息公布当日港股一度涨超16%，但随后连续多个交易日回调累计跌幅超10%。当日制药板块整体走强，行业个股中凯莱英涨10.28%、中国生物制药涨2.51%，板块联动亦提振市场情绪。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01276"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636845172","title":"恒瑞医药：每股派0.2元，股权登记日为5月26日","url":"https://stock-news.laohu8.com/highlight/detail?id=2636845172","media":"南方财经网","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636845172?lang=zh_cn&edition=full","pubTime":"2026-05-20 18:21","pubTimestamp":1779272460,"startTime":"0","endTime":"0","summary":"南财智讯5月20日电，恒瑞医药发布2025年年度权益分派实施公告，公司本次利润分配方案为每股派发现金红利0.2元（含税），共计派发现金红利12.74亿元。本次权益分派股权登记日为2026年5月26日。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202605203743627742.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU2580892789.USD","LU1997244956.HKD","LU1997245094.SGD","BK0183","LU1023057109.AUD","LU2097828631.EUR","LU2495084118.USD","BK0188","LU1997245177.USD","BK0012","LU1820825898.SGD","LU2543165471.USD","LU0359201885.HKD","LU1580142542.USD","LU0405327494.USD","LU2097828714.EUR","BK0060","LU0359202008.SGD","LU1781817850.SGD","LU2328871848.SGD","LU2097828474.EUR","LU2289578879.USD","LU1064131003.USD","LU1146622755.USD","LU0405327148.USD","BK1191","LU2097828557.USD","LU2097828805.USD","LU1328615791.USD","BK0196","BK0028","LU1969619763.USD","LU2148510915.USD","LU1064130708.USD","BK0239","LU1255011170.USD","LU0359201612.USD","LU2488822045.USD","LU1655091616.SGD","LU2580892862.HKD","01276","600276"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636814105","title":"智通AH统计|5月20日","url":"https://stock-news.laohu8.com/highlight/detail?id=2636814105","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636814105?lang=zh_cn&edition=full","pubTime":"2026-05-20 16:15","pubTimestamp":1779264907,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，截止5月20日收盘，东北电气、浙江世宝、弘业期货分列AH溢价率前三位，溢价率分别为583.54%、378.80%、325.76%；宁德时代、兆易创新、药明康德分列AH溢价率末三位，溢价率分别为-25.01%、-24.34%、-4.49%。其中安德利果汁、南华期货股份、新天绿色能源的偏离值位居前三，分别为59.87%、39.10%、37.43%；另外，上海电气、龙旗科技、中国交通建设的偏离值位居后三，分别为-36.77%、-22.21%、-16.97%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1443916.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02338","82318","00895","IE00BPRC5H50.USD","01349","00956","00300","09611","00568","06613","02691","399300","LU1242518857.USD","03986","01276","01800","06127","03678","02880","01057","02318","06031","03296","601318","LU1960683339.HKD","PNGAY","01288","EWH","01812","02359","02628","03145","03750","01033","02727","HPAD.SI","03968","00638","03143","00553","01108","PAImain","03328","00187","02476","01339","00042","159982","02218"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636896784","title":"深耕肠外营养领域，恒瑞医药新产品获批强化管线矩阵｜医药早参","url":"https://stock-news.laohu8.com/highlight/detail?id=2636896784","media":"每日经济新闻","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636896784?lang=zh_cn&edition=full","pubTime":"2026-05-20 09:22","pubTimestamp":1779240142,"startTime":"0","endTime":"0","summary":"截至5月19日收盘，市场探底回升，沪指、深成指先后翻红。医药ETF（512120）收平，港股通生物科技ETF（159102）上涨0.27%。相关个股中，恒瑞医药下跌1.6%、药明合联上涨3.28%、科伦博泰生物上涨1.27%、万泰生物下跌1.93%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202605203742884813.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202605203742884813.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU1820825898.SGD","BK0060","09939","LU2097828805.USD","LU2097828714.EUR","01276","LU1997245177.USD","LU1023057109.AUD","LU1146622755.USD","BK0188","LU2097828631.EUR","LU2580892862.HKD","600276","LU2097828557.USD","LU2289578879.USD","LU2097828474.EUR","LU2488822045.USD","BK1191","LU0359201885.HKD","LU0405327148.USD","BK0012","BK0239","LU1255011170.USD","LU1969619763.USD","LU2148510915.USD","LU2543165471.USD","LU1997245094.SGD","LU1781817850.SGD","LU2328871848.SGD","LU1997244956.HKD","LU1580142542.USD","BK1161","BK0196","BK0028","BK1515","LU0359201612.USD","LU1064130708.USD","LU1064131003.USD","LU1655091616.SGD","LU1328615791.USD","159938","BK1574","LU2495084118.USD","LU2580892789.USD","BK0183","LU0359202008.SGD","LU0405327494.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636837763","title":"恒瑞医药(01276)：ω-3 甘油三酯（2%）中/长链脂肪乳/氨基酸（16）/葡萄糖（30%）获得药品注册批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2636837763","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636837763?lang=zh_cn&edition=full","pubTime":"2026-05-19 18:18","pubTimestamp":1779185930,"startTime":"0","endTime":"0","summary":"智通财经APP讯，恒瑞医药 发布公告，近日，江苏恒瑞医药股份有限公司子公司福建盛迪医药有限公司收到国家药品监督管理局的通知，批准公司 ω-3 甘油三酯(2%)中/长链脂肪乳/氨基酸/葡萄糖(30%)注射液上市。截至目前，ω-3 甘油三酯(2%)中/长链脂肪乳/氨基酸/葡萄糖(30%)注射液相关项目累计研发投入约 8,390 万元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1443505.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU2289578879.USD","LU0405327494.USD","LU1255011170.USD","BK1191","LU2097828557.USD","BK0012","BK0028","LU2097828631.EUR","LU2580892789.USD","LU2097828474.EUR","LU1820825898.SGD","LU0359202008.SGD","01276","LU2495084118.USD","LU1064131003.USD","LU2580892862.HKD","LU1997245177.USD","LU2328871848.SGD","LU2097828805.USD","BK0188","LU0405327148.USD","BK0183","LU1997245094.SGD","LU1997244956.HKD","BK0060","600276","LU1969619763.USD","LU0359201885.HKD","BK0239","LU1781817850.SGD","LU1146622755.USD","LU1580142542.USD","LU1328615791.USD","LU0359201612.USD","LU1064130708.USD","LU1655091616.SGD","LU2543165471.USD","BK0196","LU1023057109.AUD","LU2488822045.USD","LU2097828714.EUR","LU2148510915.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636563834","title":"恒瑞医药子公司复方营养注射液获批上市 累计研发投入约8390万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2636563834","media":"财中社","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636563834?lang=zh_cn&edition=full","pubTime":"2026-05-19 17:12","pubTimestamp":1779181920,"startTime":"0","endTime":"0","summary":"5月19日，恒瑞医药（600276/01276）发布公告，公司子公司福建盛迪医药有限公司收到国家药品监督管理局的通知，批准公司ω-3甘油三酯（2%）中/长链脂肪乳/氨基酸（16）/葡萄糖（30%）注射液上市。该药品为处方药，注册分类为化学药品3类，适用于当口服或肠内营养无法进行、不足或有禁忌的中重度分解代谢成人患者。截至目前，相关项目累计研发投入约为8390万元（未经审计）。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202605193742055768.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU2580892789.USD","LU1255011170.USD","LU0405327494.USD","LU1328615791.USD","LU2289578879.USD","600276","LU0359201612.USD","BK0183","LU1781817850.SGD","BK0188","LU1655091616.SGD","LU2488822045.USD","LU2328871848.SGD","LU2097828714.EUR","LU1580142542.USD","01276","LU0359202008.SGD","LU2495084118.USD","LU1820825898.SGD","BK0012","LU1969619763.USD","LU1146622755.USD","IPOS","LU1064130708.USD","LU2097828474.EUR","LU0405327148.USD","LU2097828805.USD","BK0060","LU2580892862.HKD","LU2097828631.EUR","LU2097828557.USD","BK0196","BK1191","LU1997244956.HKD","LU1023057109.AUD","LU1064131003.USD","LU1997245177.USD","LU1997245094.SGD","BK0239","LU2148510915.USD","LU2543165471.USD","LU0359201885.HKD","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636078106","title":"Schroders PLC增持恒瑞医药(01276)66.3万股 每股作价约68.7港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2636078106","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636078106?lang=zh_cn&edition=full","pubTime":"2026-05-18 19:38","pubTimestamp":1779104328,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，香港联交所最新数据显示，5月12日，Schroders PLC增持恒瑞医药(01276)66.3万股，每股作价68.7041港元，总金额约为4555.08万港元。增持后最新持股数目为1317.12万股，持股比例为5.1%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1443064.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0405327148.USD","LU1146622755.USD","LU1328615791.USD","LU2488822045.USD","LU1023057109.AUD","LU2097828631.EUR","LU2328871848.SGD","LU1820825898.SGD","LU0359202008.SGD","BK0183","LU1580142542.USD","LU2580892862.HKD","BK0012","BK0060","BK0188","BK0239","LU2097828557.USD","01276","LU2543165471.USD","LU1655091616.SGD","BK1191","LU0359201612.USD","LU1997244956.HKD","BK0196","BK0028","LU0405327494.USD","LU2289578879.USD","LU1064130708.USD","600276","LU1781817850.SGD","LU2148510915.USD","LU1255011170.USD","LU2097828474.EUR","LU2097828805.USD","LU1997245177.USD","EWH","LU0359201885.HKD","LU1997245094.SGD","LU1969619763.USD","LU2495084118.USD","LU2580892789.USD","LU1064131003.USD","LU2097828714.EUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636026816","title":"恒瑞医药：公司已有瑞拉芙普α、瑞康曲妥珠单抗、阿得贝利单抗等多款生物制品类创新药获批上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2636026816","media":"每日经济新闻","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636026816?lang=zh_cn&edition=full","pubTime":"2026-05-18 16:48","pubTimestamp":1779094139,"startTime":"0","endTime":"0","summary":"每经AI快讯，有投资者在投资者互动平台提问：你好，贵司2025年新成立的生物制药事业部，请问在生物制药方面有什么新的进展？","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202605183740505938.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202605183740505938.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU2580892862.HKD","LU2097828805.USD","LU1328615791.USD","BK1191","LU1580142542.USD","LU1969619763.USD","LU2580892789.USD","LU1146622755.USD","LU2289578879.USD","IPOS","01276","LU2495084118.USD","LU1781817850.SGD","LU1997244956.HKD","BK0183","BK0196","LU0405327494.USD","LU1064131003.USD","06978","LU1997245177.USD","LU1997245094.SGD","LU0405327148.USD","LU2148510915.USD","BK0060","LU2097828631.EUR","LU0359201612.USD","159992","BK0028","LU2328871848.SGD","BK0239","LU1820825898.SGD","LU2097828714.EUR","LU1655091616.SGD","600276","BK1574","LU0359202008.SGD","BK1161","LU2543165471.USD","BK0188","BK0012","LU1255011170.USD","LU0359201885.HKD","LU2488822045.USD","LU1064130708.USD","LU2097828557.USD","LU1023057109.AUD","LU2097828474.EUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635792414","title":"恒瑞医药：RSS0393乳胶获临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2635792414","media":"南方财经网","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2635792414?lang=zh_cn&edition=full","pubTime":"2026-05-14 16:37","pubTimestamp":1778747820,"startTime":"0","endTime":"0","summary":"南财智讯5月14日电，恒瑞医药公告，RSS0393乳胶收到国家药品监督管理局《药物临床试验批准通知书》，同意本品开展用于特应性皮炎治疗的临床试验。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202605143737468040.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU0359201612.USD","LU2097828805.USD","BK0028","BK0239","LU0359202008.SGD","600276","LU2097828474.EUR","LU2328871848.SGD","LU1997244956.HKD","LU1969619763.USD","LU1997245094.SGD","LU2495084118.USD","LU2097828714.EUR","LU1064130708.USD","LU1781817850.SGD","LU2580892789.USD","LU1255011170.USD","LU1655091616.SGD","LU2097828557.USD","LU0359201885.HKD","LU2580892862.HKD","LU1820825898.SGD","BK0196","LU0405327148.USD","BK0183","LU0405327494.USD","BK0060","LU2289578879.USD","LU1146622755.USD","LU1328615791.USD","LU2543165471.USD","LU1997245177.USD","LU2097828631.EUR","BK0188","LU2148510915.USD","BK1191","LU2488822045.USD","LU1064131003.USD","BK0012","LU1580142542.USD","01276","LU1023057109.AUD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635792748","title":"恒瑞医药(600276.SH)子公司SHR-3079注射液获批开展临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=2635792748","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2635792748?lang=zh_cn&edition=full","pubTime":"2026-05-14 16:36","pubTimestamp":1778747819,"startTime":"0","endTime":"0","summary":"智通财经APP讯，恒瑞医药(600276.SH)发布公告，近日，子公司苏州盛迪亚生物医药有限公司收到国家药品监督管理局核准签发关于SHR-3079注射液《药物临床试验批准通知书》，将于近期开展临床试验。据悉，SHR-3079注射液是公司自主研发的创新型抗肿瘤药物，拟用于治疗B细胞非霍奇金淋巴瘤。经查询，目前国内外尚无同类药物获批上市。截至目前，SHR-3079注射液相关项目累计研发投入约为2340万元(未经审计)。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1441697.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["01276","LU1997245094.SGD","BK0012","LU2097828557.USD","LU0405327148.USD","BK0239","LU2543165471.USD","LU1255011170.USD","LU1023057109.AUD","BK0183","LU1328615791.USD","LU1655091616.SGD","LU0359201885.HKD","LU0359201612.USD","LU1997244956.HKD","BK0060","LU2289578879.USD","LU0359202008.SGD","BK0196","BK1191","BK0188","BK0028","LU1146622755.USD","LU2097828474.EUR","LU2580892862.HKD","LU2097828714.EUR","LU1969619763.USD","LU2580892789.USD","LU2097828631.EUR","LU2328871848.SGD","LU2488822045.USD","LU1064131003.USD","LU1820825898.SGD","LU1064130708.USD","LU0405327494.USD","LU2495084118.USD","LU1781817850.SGD","LU2097828805.USD","600276","LU1997245177.USD","LU2148510915.USD","LU1580142542.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635794944","title":"智通AH统计|5月14日","url":"https://stock-news.laohu8.com/highlight/detail?id=2635794944","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2635794944?lang=zh_cn&edition=full","pubTime":"2026-05-14 16:15","pubTimestamp":1778746506,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，截止5月14日收盘，东北电气、浙江世宝、弘业期货分列AH溢价率前三位，溢价率分别为575.00%、366.67%、313.94%；宁德时代、兆易创新、招商银行分列AH溢价率末三位，溢价率分别为-25.44%、-17.12%、-4.61%。其中大唐发电、南华期货股份、安德利果汁的偏离值位居前三，分别为128.05%、57.70%、54.74%；另外，龙旗科技、中国人寿、中国交通建设的偏离值位居后三，分别为-18.16%、-16.21%、-15.00%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1441686.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02218","01057","02318","601318","03996","EWH","PAImain","00042","09981","00568","02338","HPAD.SI","06166","PNGAY","00811","03968","02899","03296","03678","01800","03143","03328","09611","LU0543330483.HKD","00300","01033","06127","03750","00553","01349","03986","00323","09989","02359","03145","01108","02628","00991","399300","01276","00187","00981","06826","IE00BYV24P56.USD","01812","LU0898667661.SGD","02691","159982","82318"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635320782","title":"携手推进肿瘤学、血液学及免疫学创新疗法 恒瑞医药与百时美施贵宝达成战略合作协议","url":"https://stock-news.laohu8.com/highlight/detail?id=2635320782","media":"经济参考网","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2635320782?lang=zh_cn&edition=full","pubTime":"2026-05-13 17:20","pubTimestamp":1778664054,"startTime":"0","endTime":"0","summary":"5月12日，江苏恒瑞医药股份有限公司(简称“恒瑞医药”，600276.SH;01276.HK)与百时美施贵宝公司(简称“BMS”，NYSE：BMY)宣布达成全球战略合作及许可协议，共同推进13款涵盖肿瘤学、血液学及免疫学领域的早期创新项目。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202605133735980065.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU2328871848.SGD","LU0882574055.USD","LU0432979614.USD","LU1820825898.SGD","LU1023057109.AUD","IE00B2B36J28.USD","LU0405327494.USD","LU0225771236.USD","BK0183","LU1670710588.SGD","LU1868837300.USD","LU1655091616.SGD","LU2097828714.EUR","LU2242646821.SGD","IE0009355771.USD","600276","LU1868836757.USD","BK0060","LU0321505439.SGD","LU0985481810.HKD","LU2097828805.USD","LU2242652126.USD","LU0405327148.USD","LU1571399168.USD","LU0237698245.USD","LU1146622755.USD","LU0306807586.USD","LU1064131003.USD","01276","BK0012","LU1585245621.USD","LU0359201612.USD","LU2097828474.EUR","IE00BFXG1179.USD","LU1670710661.SGD","BMY","LU1997245177.USD","LU2543165471.USD","LU1261432733.SGD","LU1093756168.USD","BK4007","LU1670711040.USD","LU2495084118.USD","IE00BFTCPJ56.SGD","BK4532","LU0225284248.USD","LU2097828557.USD","LU2580892862.HKD","LU2125154778.USD","LU1868836591.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635040892","title":"恒瑞医药子公司获三项临床批件","url":"https://stock-news.laohu8.com/highlight/detail?id=2635040892","media":"财中社","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2635040892?lang=zh_cn&edition=full","pubTime":"2026-05-13 16:52","pubTimestamp":1778662320,"startTime":"0","endTime":"0","summary":"5月13日，恒瑞医药（600276/01276）发布公告，公司子公司苏州盛迪亚生物医药有限公司、上海盛迪医药有限公司近日收到国家药品监督管理局核准签发的关于SHR-3821注射液、阿得贝利单抗注射液、瑞拉芙普α注射液的《药物临床试验批准通知书》，将于近期开展临床试验。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202605133735945731.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU1328615791.USD","LU1820825898.SGD","01276","LU0405327148.USD","LU2289578879.USD","LU2580892862.HKD","BK0028","LU1580142542.USD","BK1191","LU2097828805.USD","BK0060","LU2097828474.EUR","BK0012","LU2097828631.EUR","LU1969619763.USD","LU2097828557.USD","BK0183","LU1023057109.AUD","LU1655091616.SGD","LU0359201612.USD","LU2097828714.EUR","LU2580892789.USD","LU2488822045.USD","LU2148510915.USD","LU1146622755.USD","600276","LU1064130708.USD","LU1255011170.USD","LU1997245094.SGD","LU2495084118.USD","BK0188","LU0359201885.HKD","LU1997245177.USD","LU0359202008.SGD","LU2328871848.SGD","LU1781817850.SGD","LU1997244956.HKD","LU0405327494.USD","LU2543165471.USD","BK0239","BK0196","LU1064131003.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635920479","title":"恒瑞医药：SHR-3821注射液获临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2635920479","media":"南方财经网","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2635920479?lang=zh_cn&edition=full","pubTime":"2026-05-13 16:47","pubTimestamp":1778662020,"startTime":"0","endTime":"0","summary":"南财智讯5月13日电，恒瑞医药公告，SHR-3821注射液收到国家药品监督管理局《药物临床试验批准通知书》，同意开展SHR-3821注射液联合其他抗肿瘤治疗在实体瘤患者中的安全性、耐受性和有效性的多中心、开放的Ib/II期临床研究。该药为公司自主研发的人源化抗体药物，拟用于治疗晚期实体瘤，可通过在肿瘤组织中特异性激活免疫细胞发挥抗肿瘤作用。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202605133735943423.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU1328615791.USD","LU1820825898.SGD","01276","LU0405327148.USD","LU2289578879.USD","LU2580892862.HKD","BK0028","LU1580142542.USD","BK1191","LU2097828805.USD","BK0060","LU2097828474.EUR","BK0012","LU2097828631.EUR","LU1969619763.USD","LU2097828557.USD","BK0183","LU1023057109.AUD","LU1655091616.SGD","LU0359201612.USD","LU2097828714.EUR","LU2580892789.USD","LU2488822045.USD","LU2148510915.USD","LU1146622755.USD","600276","LU1064130708.USD","LU1255011170.USD","LU1997245094.SGD","LU2495084118.USD","BK0188","LU0359201885.HKD","LU1997245177.USD","LU0359202008.SGD","LU2328871848.SGD","LU1781817850.SGD","LU1997244956.HKD","LU0405327494.USD","LU2543165471.USD","BK0239","BK0196","LU1064131003.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635027823","title":"大摩：恒瑞医药(01276)与BMS缔152亿美元战略合作 加速全球化进程","url":"https://stock-news.laohu8.com/highlight/detail?id=2635027823","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2635027823?lang=zh_cn&edition=full","pubTime":"2026-05-13 10:43","pubTimestamp":1778640196,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，摩根士丹利发布研报称，恒瑞医药(01276)与百时美施贵宝宣布一项涵盖13个临床前资产的全球战略合作，总交易价值达152亿美元(下同)。当中包括6亿美元预付款、2027至2028年合共3.5亿美元周年付款、最高143亿美元里程碑付款，以及分级销售里程权利金。该行维持恒瑞为中国医疗保健行业首选股，予“增持”评级，H股目标价92港元。该行认为，这项涵盖多种形式及资产模态的战略合作，进一步验证恒瑞医药的早期研发平台及提升的全球化能力。除了短期现金收益外，双向合作结构及共同开发与商业化选项，亦有望加快恒瑞的全球化步伐，并为其在中国市场不断扩展的免疫学产品组合带来商业协同效应。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"d8fdac8d3d9097cb034fb43ab6bd5883","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1441038.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0359201612.USD","LU2097828805.USD","BK0028","BK0239","LU0359202008.SGD","600276","LU2097828474.EUR","LU2328871848.SGD","LU1997244956.HKD","LU1969619763.USD","LU1997245094.SGD","LU2495084118.USD","LU2097828714.EUR","LU1064130708.USD","LU1781817850.SGD","LU2580892789.USD","LU1255011170.USD","LU1655091616.SGD","LU2097828557.USD","LU0359201885.HKD","LU2580892862.HKD","LU1820825898.SGD","BK0196","LU0405327148.USD","BK0183","LU0405327494.USD","BK0060","LU2289578879.USD","LU1146622755.USD","LU1328615791.USD","LU2543165471.USD","LU1997245177.USD","LU2097828631.EUR","BK0188","LU2148510915.USD","BK1191","LU2488822045.USD","LU1064131003.USD","BK0012","BMS","LU1580142542.USD","01276","LU1023057109.AUD"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.hrs.com.cn","stockEarnings":[{"period":"1week","weight":-0.0301},{"period":"1month","weight":-0.1306},{"period":"3month","weight":-0.1197},{"period":"6month","weight":-0.1982},{"period":"1year","weight":0.1147},{"period":"ytd","weight":-0.1599}],"compareEarnings":[{"period":"1week","weight":-0.0077},{"period":"1month","weight":-0.0146},{"period":"3month","weight":-0.0436},{"period":"6month","weight":-0.0134},{"period":"1year","weight":0.0995},{"period":"ytd","weight":-0.0012}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"江苏恒瑞医药股份有限公司是一家主要从事药品的研发、生产和销售的中国公司。该公司专注于肿瘤领域，覆盖激酶抑制剂、抗体偶联药物（ADC）、肿瘤免疫、激素受体调控、脱氧核糖核酸（DNA）修复及表观遗传、支持治疗等研究领域。该公司的产品包括抗肿瘤、镇痛麻醉和造影剂，应用于自身免疫疾病、代谢性疾病、心血管疾病、感染疾病、呼吸系统疾病、血液疾病、疼痛管理、神经系统疾病、眼科、肾病等领域。该公司主要在国内外市场开展其业务。","exchange":"SEHK","name":"恒瑞医药","nameEN":"HENGRUI PHARMA"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"恒瑞医药(01276)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供恒瑞医药(01276)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"恒瑞医药,01276,恒瑞医药股票,恒瑞医药股票老虎,恒瑞医药股票老虎国际,恒瑞医药行情,恒瑞医药股票行情,恒瑞医药股价,恒瑞医药股市,恒瑞医药股票价格,恒瑞医药股票交易,恒瑞医药股票购买,恒瑞医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"恒瑞医药(01276)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供恒瑞医药(01276)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}